Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting

Study Identifier:
CHIT-2301
ClinicalTrials.gov Identifier:
NCT06100042
EudraCT Identifier:
N/A
EU CT ID:
N/A
Study Contact Information:
N/A
Active, not recruiting

Study Details

Medical Condition
  • Asthma
Study Drug
  • Drug: BDP/FF/G
Date
Apr 2024 - Jun 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Inclusion and Exclusion Criteria
Inclusion Criteria
  • Patients ≥ 18 years of age;
  • Patients with confirmed leading diagnosis of asthma with or without concomitant COPD;
  • Physician decision to start fixed triple therapy with ICS/LABA/LAMA (BDP/FF/G) MS or HS according to its current authorised indication and current reimbursement conditions within the Italian National Health System. The treatment decision must be made independently from participation in this study and may have started within the previous 4 weeks (maximum);
  • Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study.
Exclusion Criteria
  • Participation in an interventional clinical trial within 30 days prior to enrolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.
Healthy Volunteers
No

Protocol Summary

TriMaximize is a non-interventional study aimed to collect prospective data from asthmatic patients under routine care, for whom their treating physician has decided to prescribe BDP/FF/G (beclomethasone/formoterol/glycopyrronium).

Study Locations

Location
Status
Location
U.O. Clinica Psichiatrica e SPDC. Ospedale Policlinico S. Martino - IRCCS, Genova
Genoa, Italy
Status
N/A